Replies to post #205492 on Biotech Values

[DewDiligence]

ADXS—Logically, it's not that big a deal, but it may explain a good bit of the weakness in the stock during the past month or so.

AZN paused enrollment in its H&N trials in mid-September, but didn't formally acknowledge it until today.